Cardiff Oncology Inc
CRDF2.560USD
-0.080-3.03%
交易中 （美东）报价延迟15分钟
170.31M总市值
亏损市盈率 TTM
关于 Cardiff Oncology Inc 公司
Cardiff Oncology, Inc. 是一家临床阶段的生物技术公司。该公司利用 PLK1 抑制剂（一种经过充分验证的肿瘤药物靶点）开发针对一系列具有未满足医疗需求的癌症的新型疗法。该公司专注于 RAS 突变转移性结直肠癌 (mCRC) 等适应症的临床项目，以及转移性胰腺导管腺癌 (mPDAC)、小细胞肺癌 (SCLC) 和三阴性乳腺癌 (TNBC) 的研究者发起的试验。其主要候选药物 Onvansertib 是一种口服小分子候选药物，对 PLK1 抑制剂具有高度特异性，半衰期为 24 小时。该公司有五项正在进行和计划中的 onvansertib 临床试验：一项试验（CRDF-004）针对 RAS 突变的 mCRC 患者的一线治疗，一项试验（CRDF-001）针对 mPDAC 患者的二线治疗，以及三项研究者发起的试验，分别针对一线 mPDAC、复发性 SCLC 和不可切除的局部晚期或转移性 TNBC。
公司简介
公司代码CRDF
公司名称Cardiff Oncology Inc
上市日期Jul 27, 2004
CEODr. Mark Erlander, Ph.D.
员工数量32
证券类型Ordinary Share
年结日Jul 27
公司地址11055 Flintkote Ave
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18589527570
网址https://cardiffoncology.com/
公司代码CRDF
上市日期Jul 27, 2004
CEODr. Mark Erlander, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
20.00K
--
Dr. Tod Smeal, Ph.D.
Dr. Tod Smeal, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger Sidhu, M.D.
Dr. Roger Sidhu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
收入明细
FY2025Q1
FY2024
FY2023
FY2022
暂无数据
地区USD
名称
营收
占比
United States
109.00K
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
持股股东
持股股东
占比
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
股东类型
持股股东
占比
Investment Advisor
17.41%
Hedge Fund
14.56%
Investment Advisor/Hedge Fund
8.49%
Research Firm
5.32%
Corporation
3.63%
Individual Investor
2.01%
Private Equity
0.86%
Bank and Trust
0.18%
Insurance Company
0.03%
Other
47.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
209
34.93M
52.51%
+1.36M
2025Q1
212
33.90M
51.14%
+3.13M
2024Q4
197
29.71M
44.66%
+10.83M
2024Q3
176
18.97M
39.69%
-1.89M
2024Q2
177
19.40M
43.04%
+3.79M
2024Q1
190
14.89M
33.18%
-2.33M
2023Q4
185
11.58M
25.77%
-8.71M
2023Q3
197
11.37M
25.45%
-9.63M
2023Q2
203
11.90M
26.66%
-13.64M
2023Q1
216
12.90M
29.30%
-10.68M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Commodore Capital LP
5.38M
8.09%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.12M
4.68%
+830.45K
+36.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
5.32%
+907.00K
+34.45%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
1.75M
2.63%
+1.47M
+520.96%
Mar 31, 2025
Pfizer Inc
2.41M
3.63%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.45M
2.17%
+152.69K
+11.82%
Mar 31, 2025
Acorn Capital Advisors, LLC
1.44M
2.17%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.39M
2.1%
+411.55K
+41.87%
Mar 31, 2025
Pace (Gary William)
1.06M
1.59%
+7.80K
+0.74%
Apr 28, 2025
State Street Global Advisors (US)
940.28K
1.41%
+91.70K
+10.81%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Vanguard US Momentum Factor ETF
0.05%
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
查看更多
Vanguard US Momentum Factor ETF
占比0.05%
iShares Micro-Cap ETF
占比0.04%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
